Clinical Trial

Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, multicenter, single-arm clinical study designed to evaluate the efficacy and safety of Polatuzumab Vedotin combined with Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as salvage therapy for relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL) patients ineligible for autologous transplantation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-25.
Trial Details
NCT Number NCT07001540
Lead Sponsor Fudan University
Collaborators: Fujian Cancer Hospital
Conditions Diffuse Large B-Cell Lymphoma
Enrollment 130 participants
Start Date 2025-05-08
Primary Completion 2027-11-15 (estimated)
Study Completion 2027-11-15 (estimated)
Updated on ClinicalTrials.gov 2025-06-19